Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Puma Biotechnology (PBYI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 896,818
  • Shares Outstanding, K 38,130
  • Annual Sales, $ -82,880 K
  • Annual Income, $ 77,960 K
  • 36-Month Beta 0.22
  • Price/Sales 35.12
  • Price/Cash Flow N/A
  • Price/Book 20.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.99
  • Number of Estimates 2
  • High Estimate -0.93
  • Low Estimate -1.05
  • Prior Year -1.71
  • Growth Rate Est. (year over year) +42.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.14 +14.24%
on 11/14/18
24.93 -3.13%
on 12/04/18
+2.03 (+9.18%)
since 11/12/18
3-Month
17.60 +37.22%
on 11/02/18
50.75 -52.41%
on 09/13/18
-25.55 (-51.41%)
since 09/12/18
52-Week
17.60 +37.22%
on 11/02/18
106.30 -77.28%
on 12/14/17
-75.45 (-75.75%)
since 12/12/17

Most Recent Stories

More News
Investor Expectations to Drive Momentum within CatchMark Timber Trust, Edison International, Puma Biotechnology, Maxim Integrated Products, Wabash National, and Resolute Energy -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CatchMark Timber Trust,...

CTT : 7.83 (-0.51%)
EIX : 59.54 (+1.10%)
PBYI : 24.15 (+2.68%)
REN : 32.55 (+2.42%)
MXIM : 54.18 (+2.05%)
WNC : 13.61 (+1.87%)
Downtrend Call Working As Puma Biotechnolo Stock Falls 43.7% (PBYI)

SmarTrend identified a Downtrend for Puma Biotechnolo (NASDAQ:PBYI) on October 10th, 2018 at $42.84. In approximately 2 months, Puma Biotechnolo has returned 43.67% as of today's recent price of $24.13....

PBYI : 24.15 (+2.68%)
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that in connection with the appointment of Maximo F. Nougues as Puma's Chief Financial Officer, the Compensation...

PBYI : 24.15 (+2.68%)
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2018...

PBYI : 24.15 (+2.68%)
Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the subgroup of patients with hormone receptor positive (HR-positive) breast cancer from...

PBYI : 24.15 (+2.68%)
Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma's drug neratinib at the 2018 San Antonio Breast...

PBYI : 24.15 (+2.68%)
45.8% Return Seen to Date on SmarTrend Puma Biotechnolo Call (PBYI)

SmarTrend identified a Downtrend for Puma Biotechnolo (NASDAQ:PBYI) on October 10th, 2018 at $42.84. In approximately 2 months, Puma Biotechnolo has returned 45.75% as of today's recent price of $23.24....

PBYI : 24.15 (+2.68%)
Why Is Puma Biotech (PBYI) Down 39.8% Since Last Earnings Report?

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PBYI : 24.15 (+2.68%)
Puma Biotechnolo Shares Down 45.9% Since SmarTrend's Sell Call (PBYI)

SmarTrend identified a Downtrend for Puma Biotechnolo (NASDAQ:PBYI) on October 10th, 2018 at $42.84. In approximately 1 month, Puma Biotechnolo has returned 45.90% as of today's recent price of $23.17....

PBYI : 24.15 (+2.68%)
48.4% Return Seen to Date on SmarTrend Puma Biotechnolo Call (PBYI)

SmarTrend identified a Downtrend for Puma Biotechnolo (NASDAQ:PBYI) on October 10th, 2018 at $42.84. In approximately 1 month, Puma Biotechnolo has returned 48.37% as of today's recent price of $22.12....

PBYI : 24.15 (+2.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade PBYI with:

Business Summary

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth...

See More

Key Turning Points

2nd Resistance Point 24.98
1st Resistance Point 24.57
Last Price 24.15
1st Support Level 23.65
2nd Support Level 23.14

See More

52-Week High 106.30
Fibonacci 61.8% 72.42
Fibonacci 50% 61.95
Fibonacci 38.2% 51.48
Last Price 24.15
52-Week Low 17.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar